Skip to content Skip to footer

Health Hope Pharma Collaborates with Gilead Sciences to Advance Encequidar in Virology

Shots:

  • Health Hope Pharma (HHP) has entered into a global licensing & collaboration agreement with Gilead Sciences to advance encequidar in the field of virology
  • As per the deal, Gilead will receive exclusive global virology rights to encequidar, while HHP & Hanmi Pharm will provide drug supply, technical support, project collaboration & receive an upfront payment, development, regulatory & sales milestones, with low single-digit royalties on net sales
  • Encequidar in combination with Paclitaxel (PO) will be evaluated in a P-III trial for metastatic breast cancer, with enrolment starting in Q4’25 across the U.S., Hong Kong, & New Zealand; eventual launches are planned across the EU, Asia, & the US

Ref: PRNewsWire | Image: Health Hope Pharma and Gilead Sciences| Press Release

Related News:- Evaxion Licenses EVX-B3 Vaccine Candidate to Merck

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com